Studies have shown that higher levels of PD-1 + CD8 + T cells in the tumor microenvironment can predict better outcomes for esophageal cancer patients receiving PD-1/PD-L1 inhibitor therapy (Zhang et al. 2021; Wu et al. 2020). This evidence concerns the gene PDCD1 and esophageal cancer.